Stoke and Biogen to present zorevunersen data at epilepsy conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Dow futures hit three-month low as yields surge, Micron earnings offer support
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise 2% as China suspends fuel exports
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 1, 2025 7:30 AM ESTNew analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modification
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by... More
